FGF‐21, as a mediator of energy homeostasis, represents a target for emerging new potentially beneficial therapies for obesity, dyslipidemia, and glucose dysregulation68, 69, 70 and possibly in the development of strategies in prevention or treatment of adverse metabolic effects of antipsychotics. This evidence concerns the gene FGF21 and metabolic syndrome.